

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

**VOLUNTARY ANNOUNCEMENT
FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED
MARCH 31, 2025 OF A LISTED ASSOCIATE - LEGEND BIOTECH
CORPORATION**

This is a voluntary announcement made by GenScript Biotech Corporation (the “**Company**”).

Legend Biotech Corporation (“**Legend Biotech**”), an associate of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Selected Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) on May 13, 2025 in relation to the financial results of Legend Biotech for the first quarter ended March 31, 2025 and the recent business highlights. For details, please refer to the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000180119825000021/0001801198-25-000021-index.html> and the press release as published on Legend Biotech’s website available at <https://investors.legendbiotech.com/press-releases>.

Shareholders should note that the above financial results pertain only to Legend Biotech not to the Company itself.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, May 13, 2025

*As at the date of this announcement, the executive Directors are Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Mr. Jiange Meng (“**Mr. Robin Meng**”), Ms. Ye Wang (“**Ms. Sally Wang**”) and Dr. Li Zhu; the non-executive Director is Dr. Luquan Wang (“**Dr. Larry Wang**”); and the independent non-executive Directors are Mr. Zumian Dai (“**Mr. Edward Dai**”), Mr. Juana Pan (“**Mr. Ethan Pan**”), Mr. Yiu Leung Andy Cheung, Dr. Chenyang Shi (“**Dr. Victor Shi**”), Dr. Alphonse Galdes, Dr. Ross Grossman and Dr. John Quelch.*